title: Surgical complications and renal function after kidney alone or simultaneous pancreas-kidney transplantation: a matched comparative study.
abstract: BACKGROUND
  In selected type 1 diabetic (T1DM) patients with end-stage renal disease (ESRD), simultaneous pancreas-kidney transplantation (SPKT) offers higher long-term graft and patient survival, but also higher initial morbidity and mortality than cadaveric kidney transplantation alone (CKTA). The development of new immunosuppressive regimens and surgical approach has improved this initial outcome, but little is known about their effect on short-term renal function and surgical complications related to the renal graft.
  
  
  METHODS
  We analysed retrospectively the short-term follow-up of 45 T1DM patients consecutively transplanted during 42 months (20 SPKT and 25 CKTA) in order to compare short-term (6 months) renal allograft function and surgical complications related to the renal allograft in both groups.
  
  
  RESULTS
  There were no differences in donor characteristics. SPKT recipients had a significantly shorter time on dialysis and cold ischaemia time, with a higher number of HLA mismatches. There was no difference in acute rejection incidence, but delayed kidney graft function was less frequent in SPKT (5% vs 32%; P<0.05). Plasma creatinine level at discharge and 6 months was significantly lower in SPKT (1.1+/-0.3 vs 1.6+/-0.7; P<0.005 and 1.1+/-0.3 vs 1.5+/-0.6; P<0.05, respectively). There were no differences in surgical renal complications (haemorrhage, thrombosis or arterial stenosis, ureter leaks or stricture, lymphoceles or dehiscences). Two SPKT patients needed reintervention on the renal allograft and only one CKTA patient.
  
  
  CONCLUSIONS
  In the modern transplant era, SPKT in ESRD diabetic patients, offers a slightly better short-term kidney allograft function without significant increase in surgical morbidity, compared with CKTA.
authors.affiliation: Department of Urology, Hospital Universitario de Canarias, Ofra s/n, La Laguna 38320 Santa Cruz de Tenerife, Spain. pegutierrez@huc.canarias.org
authors.forename: Pedro
authors.initials: P
authors.lastname: Gutiérrez
authors.forename: Domingo
authors.initials: D
authors.lastname: Marrero
authors.forename: Domingo
authors.initials: D
authors.lastname: Hernández
authors.forename: Sofia
authors.initials: S
authors.lastname: Vivancos
authors.forename: Lourdes
authors.initials: L
authors.lastname: Pérez-Tamajón
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Rodríguez de Vera
authors.forename: Antonio
authors.initials: A
authors.lastname: Alarcó
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: González-Posada
mesh_terms: D000293:Adolescent; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007668:Kidney / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D009017:Morbidity; D016035:Pancreas Transplantation / Q000009:adverse effects* / Q000379:methods; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents